Company intelligence / Profile preview

Neurosterix

Ownership: Private
Development stage: Preclinical

Overview

Neurosterix is a newly launched biopharmaceutical company focused on developing allosteric modulators for neurological disorders. Its lead program is an M4 positive allosteric modulator for schizophrenia, currently in preclinical development and advancing toward clinical studies. The company leverages a proprietary high-throughput platform acquired from Addex Therapeutics to identify highly selective small molecule drugs with improved efficacy and safety profiles

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (specifically allosteric modulators)
Industry: Biotech

Drug pipeline

3 assets

NTX-253

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neurosterix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurosterix.

Explore the full profile